tbuckley/cabot-search huggingface dataset:
Abstract 3368: Prevalence and significance of drug-drug interactions among patients with lung cancer
Authors: Sawsan Rashdan, Hui Yang, Tri Le, David Hsieh, Carlos A. Alvarez, David Gerber
Journal: Cancer Research (2019)

Abstract IMPORTANCE: Significant drug-drug interactions may exclude patients from clinical trials and complicate routine clinical care. Prevalence and significance of drug-drug interaction (DDI) among cancer populations is unknown. OBJECTIVE: To determine the rate of all potential drug interactions as well as the rate of major DDIs among individuals newly diagnosed with lung cancer in a national cohort. DESIGN, SETTING, AND PARTICIPANTS: We performed a retrospective cross-sectional study of adult patients in the United States Veterans’ Affairs (VA) medical system diagnosed with lung cancer between 2003 and 2016. Data were obtained from the VA Corporate Data Warehouse. Lists and categorization of potential DDIs were obtained from the Flockhart table provided by Indiana University School of Medicine. A list of commonly prohibited medications that are associated with major DDI, was determined after 11 clinical trials protocols of tyrosine kinase inhibitors in lung cancer treatment were reviewed. MAIN OUTCOMES AND MEASURES: The primary endpoint was the prevalence of exposure to all potential DDI during the three months leading up to and including the date of lung cancer diagnosis. The secondary endpoint was the prevalence of exposure to major DDIs (prohibited medications). RESULTS: Overall, 280 068 patients were included in the study. Mean age was 70 years, 98% were male, and 72% were white. Overall, 55.9% of patients were prescribed medications associated with potential DDI, and 5.1% of patients were prescribed medications with major DDIs that would be prohibited in certain clinical trials. Among the 20 most commonly prescribed drugs associated with potential DDI, only two (gemfibrozil and phenytoin) were associated with major DDI. CONCLUSIONS AND RELEVANCE: Medications with potential DDI are commonly prescribed to patients with lung cancer. However, only about 5% of patients are prescribed medications with major DDIs that would be prohibited in certain clinical trials. Further studies to determine the true clinical risk of all potential DDIs are warranted. Note: This abstract was not presented at the meeting. Citation Format: Sawsan Rashdan, Hui Yang, Tri Le, David Hsieh, Carlos A. Alvarez, David Gerber. Prevalence and significance of drug-drug interactions among patients with lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3368.
Stress in helicopter personnel
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Familial Aggregation of Illness Chronicity in Recurrent, Early-Onset Major Depression Pedigrees
Authors: Francis Mondimore
Journal: American Journal of Psychiatry (2006)

Objective: The authors used a large sample collected for genetic studies to determine whether a chronic course of illness defines a familial clinical subtype in major depressive disorder. Method: A measure of lifetime chronicity of depressive symptoms (substantial mood symptoms most or all of the time) was tested for familial aggregation in 638 pedigrees from the Genetics of Recurrent Early-Onset Depression (GenRED) project. Results: In subjects with chronic depression, the mean age at illness onset was lower and rates of attempted suicide, panic disorder, and substance abuse were higher than among those with nonchronic depression. Chronicity was assessed in 37.8% of affected first-degree relatives of probands with chronic depression and in 20.2% of relatives of probands with nonchronic depression. Analysis using the generalized estimating equation model yielded an odds ratio of 2.52 (SE=0.39, z=6.02, p<0.0001) for the likelihood of chronicity in a proband predicting chronicity in an affected relative. With stratification by proband age at illness onset, the odds ratio for chronicity in relatives by proband chronicity status was 6.17 (SE=2.09, z=5.35, p<0.0001) in families of probands whose illness onset was before age 13 and 1.92 (SE=0.34, z=3.72, p<0.0001) in families of probands whose illness started at age 13 or later. Conclusions: These findings suggest that chronicity of depressive symptoms is familial, especially in preadolescent-onset illness. Chronicity is also associated with other indicators of illness severity in recurrent, early-onset major depression. Further study using chronicity as a subtype in the genetic analysis of depressive illness is warranted. Refinement of the definition of chronicity in depressive illness may increase the power of such studies.
National Cancer Institute Monograph 32, August 1969
Journal: JNCI Journal of the National Cancer Institute (1969)

National Cancer Institute Monograph 32, August 1969 Get access JNCI: Journal of the National Cancer Institute, Volume 43, Issue 2, August 1969, Page 517, https://doi.org/10.1093/jnci/43.2.517 Published: 01 August 1969
THE REMOTE EFFECTS OF HEAD INJURIES.
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Probable efficacy of high-dose salicylates in reducing coronary involvement in Kawasaki disease
Authors: G. Koren
Journal: JAMA (1985)

The efficacy of high-dose salicylates in reducing the coronary artery involvement of Kawasaki disease was compared in 36 children who received acetylsalicylic acid, 80 to 180 mg/kg/day, and in 18 who did not receive high-dose salicylates during the febrile phase of the disease and whose fever was controlled mainly with acetaminophen. The two groups were comparable with respect to age and body weight. In the acetylsalicylic acid—treated group, the dose was adjusted to meet the therapeutic serum concentration range (≥20 mg/dL). There were significantly more cases of coronary involvement in the nontreated group (50%) than in the salicylate-treated group (16.6%) and of coronary aneurysms (39% vs 3%). During the febrile phase of the disease, salicylate serum concentrations achieved with a given dose were on the average twofold lower than during the nonfebrile phase, owing to impaired absorption of acetylsalicylic acid. It is suggested that despite the difficulty in achieving therapeutic serum concentrations of salicylate during the febrile phase of Kawasaki disease with a dose as high as 100 mg/kg/day, this dose is potentially capable of preventing the associated coronary disease. (<i>JAMA</i>1985;254:767-769)
Rapid US Response to Ebola Threat
Journal: JAMA (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lehrbuch der Säuglingskrankheiten.
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tumor-directed PET imaging of metastases in metastatic castration-resistant prostate cancer (mCRPC) using Zr-89 labeled antiprostate-specific membrane antigen (PSMA) antibody J591.
Authors: Jarett L. Feldman, Michael J. Morris, Danny F. Martinez, Scott T. Tagawa, David M. Nanus, Stephen Barnett Solomon, Jorge A. Carrasquillo, Victor E. Reuter, Jason Stuart Lewis, Joseph A. O' Donoghue, Susan F. Slovin, Dana E. Rathkopf, Mithat Gonen, Volkan Beylergil, Jeremy C. Durack, Sarah M. Cheal, Neil Harrison Bander, Howard I. Scher, Steven M. Larson, Neeta Pandit-Taskar
Journal: Journal of Clinical Oncology (2015)

5054 Background: There is no standard imaging (SI) modality that specifically and accurately images prostate cancer (PC) metastases, hampering prognostication and response assessment. J591 is a humanized antibody that targets the external domain of PSMA. We have previously reported on the feasibility, PK and biodistribution of 89Zr-J591 in 10 patients (pts) (Pandit-Taskar et al, Eur J Nuc Med Img 2014). We now report on the targeting/accuracy in 50 pts with mCRPC. Methods: Following standard CT/MRI, bone scan (BS), and FDG PET imaging, 5 mCi of 89Zr-J591 was administered IV. 89Zr-J591 was imaged 6-8 days after injection. Positive (pos) scan findings were confirmed, where possible, with biopsies (bxs) in the following preference: concordant 89Zr-J591 and FDG pos, 89Zr-J591 and FDG mismatch, and a mismatch between SI and any PET. Results: Imaging: A total of 703 lesions in 50 pts were identified using all imaging modalities. Bone:538 total bone lesions were detected. 491(91%) lesions were present on J591 of which 99 were only evident by J591. BS identified 339 (63%), CT 301 (56%), and FDG 207 (38%). Soft Tissue: 165 total soft tissue lesions were detected. 90 (55%) were seen on J591 of which 17 were only evident by J591. CT identified 124 (75%) and FDG 88 (53%). Pathology:46 bx’s were evaluable (21 bone, 25 soft tissue) in 34 pts. Of the unique J591 lesions bx’d, 5/7 were pos for PC. Bone: We bx’d 19 J591 pos lesions and 2 J591 neg sites. Overall, path concordance with J591 was: 89% true pos, 100% true neg, 11% false pos, and 0% false neg. Soft tissue: We bx’d 16 J591 pos lesions and 9 J591 neg sites. Of these, we found 88% true pos, 11% true neg, 13% false pos, and 89% false neg. Conclusions: J591 PET identifies additional disease in bone not seen using other imaging modalities. These lesions are highly likely to correspond to disease by bx. The data also continues to affirm that J591 appears to be superior at identifying bony disease than soft tissue lesions. Clinical trial information: NCT01543659.
Parallel 38: Molecular Mechanisms of Liver Injury and Carcinogenesis
Journal: Hepatology (2015)

BACKGROUND: Interferon (IFN)-based therapy for HCV postliver transplant (LT) has been associated with suboptimal response and poor tolerability.New IFN-free regimens have the potential to improve response rates and safety.The all-oral, pangenotypic regimen of daclatasvir (DCV) and sofosbuvir (SOF) with ribavirin (RBV) was well tolerated and achieved high SVR rates in patients with post-LT recurrence or advanced cirrhosis in the ALLY-1 study.We report here a detailed subanalysis of LT recipients with HCV recurrence from a compassionate use program (CUP) of DCV+SOF±RBV.METHODS: This multicenter CUP, opened in 5 European countries, enrolled adult patients with chronic HCV infection who are at a high risk of hepatic decompensation or death within 12 months if left untreated, and who had no available treatment options.Patients received DCV 60mg + SOF 400mg once daily for 24 weeks, with RBV added at the physician's discretion.This interim analysis includes 87 post-LT patients enrolled in the CUP with available data on March 16, 2015, of whom 38 patients have SVR12 data available to date.RESULTS: Most patients were male (69%), white (93%), with a median age of 58 years (39-75).Mean (SD) baseline HCV RNA 5.8 (1.7) log 10 IU/ mL.Most patients were infected with HCV GT1 (87%) (1a, n=28; 1b, n=37; 1 unknown, n=11) or GT3 (8%).Median time since LT to treatment initiation was 3.3 years.Most frequent immunosuppressant includes tacrolimus (n=47) and cyclosporine (n=11).Cirrhosis was present in 35 (40%) patients; among cirrhotic patients, 13 (37%) were Child-Pugh class B/C, and 8 (23%) had MELD scores ≥15.Twenty-six (30%) patients received RBV as part of the regimen.Baseline characteristics and results for each treatment group are described in the Table .Overall, of the 38 patients with available HCV RNA values at posttreatment week 12 to date, all achieved virologic response (SVR12 100%).Updated SVR12 data will be presented.Serious AEs occurred in 18 patients (21%), 6 patients discontinued treatment due to AEs and 3 patients died.CONCLUSION: In this preliminary analysis of patients in a real-world setting, DCV+SOF±RBV achieved high rates of SVR12 and was well tolerated in this difficult-to-treat post-liver transplant patient population.The use of ribavirin did not affect efficacy outcomes.
Commentaire de travail de S.-E. Kudo et al., pp. 869
Journal: Endoscopy (2011)

See also: Diagnosis of colorectal lesions with a novel endocytoscopic classification – a pilot studyEndoscopy 2011; 43(10): 869-875DOI: 10.1055/s-0030-1256663 Corrected by: Commentaire de travail de S.-E. Kudo et al., pp. 869Endoscopy 2012; 44(03): 308-308DOI: 10.1055/s-0032-1306678
Subacute Hepatitis
Authors: William A. Tisdale
Journal: New England Journal of Medicine (1963)

ACUTE viral hepatitis of both the epidemic and *■ serum varieties continues to be a common medical illness and is regarded correctly as a typical benign, self-limited disease. Despite considerable variation in the degree and duration of clinical illness associated with the virus-induced liver-cell damage most patients recover completely, with no lasting evidence of hepatic dysfunction. Rarely, for unknown reasons, massive liver necrosis is produced by the hepatitis viruses and results clinically in usually fatal fulminant acute hepatitis. Most physicians recognize these two extremes of the hepatitis clinicopathological "spectrum," — acute benign hepatitis and fatal fulminant hepatitis, — but . . .
Leads from the MMWR. Human ehrlichiosis--United States
Journal: JAMA (1988)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 1697: Molecular features of refractory metastatic breast cancer
Authors: Zhanhong Chen, Yuzi Zhang, Jing Zhao, Shangli Cai, Yongmei Yin
Journal: Cancer Research (2019)

Abstract Background: Breast cancer is the most frequently diagnosed cancer in women worldwide and metastatic disease remains generally incurable, indicating a need for new drug discovery for metastatic breast cancer. In this study, we investigated the molecular features of refractory metastatic breast cancer. Methods: 74 metastatic refractory breast cancer patients who received molecular screening using next generation sequencing (NGS) between 2015 and 2017 were included in this analysis. Clinical and pathologic characteristics of these patients were reviewed. Results: Among the 74 patients, 27%, 51.4%, 10.8%, 10.8% had hormone receptor (HR)-negative HER2-negative, HR-positive HER2-negative, HR-positive HER2-positive, HR-negative HER2 positive. 54.1%, 48.6%, 9.5%, 47.3% had liver, lung, brain, bone metastasis. The most significantly mutated genes in refractory HR-positive breast tumors included TP53 (54.3%), PIK3CA (52.2%), CCND1 (19.6%) and ESR1 (15.2%). The most significantly mutated genes in refractory HR-negative breast tumors included TP53 (82.1%), PIK3CA (50%), MYC (14.3%), NF1 (14.3%) and KRAS (10.7%). Genes in PI3K/AKT/mTOR pathway were significantly mutated in 76.1% of HR-positive and 82.1% of HR-negative refractory breast tumors, respectively. Mutation of genes involved in DNA damage response pathway were observed in 23.9% of HR-positive tumors and 32.1% of HR-negative tumors. 21.7% of HR-positive tumors and only 3.6% of HR-negative tumors harbored at least one gene alteration in FGFR pathway (P = 0.04). 30.4% (17/74) of HR-positive tumors and 10.7% (3/28) of HR-negative tumors carried at least one gene alteration in CDK pathway (P = 0.50). 63.6% of tumors with alterations in FGFR pathway concurrently harbored alterations in CDK pathway. Alterations in FGFR or CDK pathway were significantly correlated with liver metastasis (P = 0.001). In addition, TP53 mutation was significantly correlated with brain metastasis (P = 0.022). Conclusions: These results provide a better understanding of molecular targets in refractory metastatic breast cancer which may lead to an improvement in the development of novel therapeutic strategies. Citation Format: Zhanhong Chen, Yuzi Zhang, Jing Zhao, Shangli Cai, Yongmei Yin. Molecular features of refractory metastatic breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1697.
Africa on the precipice: perspective from South Africa
Authors: A. Walker
Journal: JAMA (1994)

<h3>In Reply.</h3> —Walker et al make some very helpful points. There are complex differences between evolving African countries. South Africa's mortality rate for children under 5 years of age is 72 per 1000 live births compared with 180 in least-developed countries and a mean of 101 in developing countries.<sup>1</sup>Forty-nine percent of South Africa's population is urbanized compared with a mean of 28% in sub-Saharan Africa,<sup>1</sup>while the maternal mortality rate stands at 83% in South Africa and 600 for sub-Saharan Africa. In most of Africa, 80% of the population remains rural. It is a tribute to the great advances in South Africa that it is so nonrepresentative of most of the continent. Walker et al are, of course, correct that there must be a strengthening of health facilities and infrastructure; nor must we forget referral mechanisms and secondary care. A great failing of many donors and funding
DEMEROL
Authors: Paul de Kruif
Journal: JAMA (1946)

<h3>To the Editor:—</h3> InThe Journal, July 13, H. J. Anslinger, referring to my article on Demerol in the<i>Reader's Digest</i>of June 1946, states that the drug's addiction properties were found to be similar to morphine in the U. S. Public Health Service Hospital at Lexington, Ky., and that this was confirmed by others who experimented with it. The studies to which Mr. Anslinger clearly refers are those published by Dr. C. K. Himmelsbach. The essential point of Dr. Himmelsbach's several papers is that Demerol does not possess addicting properties similar to those of morphine but even less than those of codeine. For instance, he states (<i>J. Pharmacol. &amp; Exper. Therap.</i><b>75</b>:64 [May] 1942), "Not only was the Demerol abstinence syndrome less severe than that of morphine or codeine by objective criteria, but the subjective complaints were markedly reduced." Since addiction liability to anything from coffee to morphine